预约演示
更新于：2026-05-19
Escitalopram Oxalate
草酸艾司西酞普兰
更新于：2026-05-19
概要
基本信息
简介Escitalopram 以商品名 Esertia 销售，是一种小分子药物，可作为选择性 5-羟色胺再摄取抑制剂 (SSRI)。 它以 SERT-5 转运蛋白为靶点，该靶点负责突触间隙中血清素的再摄取。 通过抑制 SERT-5 转运蛋白，Escitalopram增加了大脑中血清素的细胞外浓度，这被认为是其治疗效果的潜在机制。Escitalopram还被批准用于治疗抑郁症，并已被证明可有效减少 焦虑症和恐慌症的症状。 它也被用于其他疾病，如强迫症和创伤后应激障碍。该药由 H. Lundbeck 开发，于 2002 年 8 月 14 日在美国首次获得批准，随后陆续在中国和日本获批上市。 |
药物类型 小分子化药 |
别名 Cipralex、Entact、Escitalopram + [18] |
靶点 |
作用方式 抑制剂 |
作用机制 SERT抑制剂(5-羟色胺转运体抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS号219861-08-2 |
关联
541
项与 草酸艾司西酞普兰 相关的临床试验NCT05901571
Acupuncture and Escitalopram for Treating Major Depression Clinical Study (AE-TMDCS): Study Design of a Randomized Controlled Trial
NCT06796946
Intervention for Antidepressant Deprescription in Primary Care: a Randomized Community Clinical Trial
NCT06705478
An Open-Label, Randomized Controlled Trial of Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
100 项与 草酸艾司西酞普兰 相关的临床结果
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的转化医学
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的专利（医药）
登录后查看更多信息
1,653
项与 草酸艾司西酞普兰 相关的文献（医药）2026-05-04Expert Opinion On Drug Safety
The antidepressants and sexual dysfunction: a pharmacovigilance-pharmacodynamic study of the FDA adverse event reporting system
Article
作者: Cheng, Yu ; Xu, Qingqing ; Tan, Yingting ; Mou, Fan ; Chen, Youjun ; Qian, Ruiyi ; Wang, Wanying ; Zhao, Xue ; Yu, Shunying
BACKGROUND:
Sexual dysfunction (SD) is a commonly occurring yet often underestimated adverse event associated with the use of antidepressants. This study aimed to analyze the reporting of SD associated with the use of antidepressants in comparison with one another, and to explore potential receptor mechanisms based on the real-world data from the Food and Drug Administration Adverse Event Reporting System (FAERS).
METHODS:
Disproportionality analysis was conducted based on FAERS reports (2004 Q1 to 2024 Q2) using reporting odds ratios (ROR) and information components (IC) methods. Spearman correlation analysis was performed to explore the relationship between ROR and the related receptor-binding properties.
RESULTS:
In total, 233 significant signals involving 9767 cases were included. The analysis confirmed that the selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors exhibited significant signals, consistent with previous research. Additionally, unexpected signals were detected for vortioxetine (ROR = 13.60), suggesting a potential risk despite its low reported incidence rates of SD. Spearman correlation analysis revealed potential effects for the binding affinities of serotonin transporter, 5-HT1B, and 5-HT2A receptors on reduced sexual desire.
CONCLUSIONS:
The present investigation has detected new and unexpected signals of antidepressant-related SDs. Further research is needed to validate and clarify the observed associations.
2026-03-01Journal of Traditional and Complementary Medicine
Electroacupuncture enhances the effects of escitalopram oxalate on glucocorticoid-inducible genes, inflammation and neurotrophin in depressed patients
Article
作者: Shi, Chuan ; Zhao, Bingcong ; Wang, Yangpeng ; Li, Jing ; Jiang, Huili ; Gao, Xingzhou ; Feng, Shixing ; Yang, Xinjing ; Zhang, Zhangjin ; Bao, Tuya
Background and aim:
Evidence proved that electroacupuncture (EA) combined with antidepressants can improve the antidepressant effectiveness for depressed patients. However, the clinical mechanisms of EA remain unclear. This study aimed to observe the mechanism of EA as an adjunct therapy to escitalopram oxalate (EO) on depressed patients.
Experimental procedure:
This study was designed as a single-blinded, double-dummy randomized controlled trial. 61 participants were diagnosed with mild-to-moderate depression according to the International Classification of Diseases 10th Edition (ICD-10, F32) were randomly allocated to receive EA + EO placebo, EO + sham EA, or EA + EO for six weeks treatment. The clinical assessment including depression severity, quality of life (QOL) and clinical safety. Biological indicators of immune-inflammation, the brain-derived neurotrophic factor and glucocorticoid inducible genes in peripheral blood of participants were measured by using enzyme linked immunosorbent assay and real-time polymerase chain reaction respectively before and after treatment.
Results and conclusion:
Three interventions improved the depression severity and QOL (P < 0.05), and no inter-group difference was found in the 6th week (P > 0.05). Anxiety psychic and somatic general symptoms in the EA + EO group were improved significantly than those of the other two groups (P < 0.05). After six-week treatment of EA + EO, blood SGK1 mRNA, GILZ mRNA, and BDNF levels were increased significantly (P < 0.05), and IL-6 levels were decreased significantly (P < 0.05) in depressed patients. IL-6 change levels were positively correlated with the change of HAMD-24 score in patients who received EA + EO treatment (P < 0.05). EA as an add-on therapy of EO probably enhanced antidepressant effectiveness through regulating multiple targets involved in blood BDNF, IL-6, and glucocorticoid-inducible genes GILZ mRNA and SGK-1 mRNA.
2025-11-01INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE
Quetiapine combined with escitalopram in the treatment of bipolar depression
Article
作者: Peng, Haiying ; Huang, Jinchang ; Liu, Xueqin ; Xiong, Zheng ; Zhang, Pingping
Objectives:
To assess the efficacy of escitalopram combined with quetiapine vs quetiapine alone in the treatment of depressive episodes of bipolar disorder (BPD).
Methods:
Eighty-eight hospitalized patients with a BPD depressive episode were recruited into the study. All patients were randomized to a control group (n = 44) or the intervention group (n = 44). Members of the control group received quetiapine fumarate alone, with an initial dose 50 mg twice/day; the dose was increased by 50-100 mg daily until 300-600 mg/d was reached. The treatment group received quetiapine at the same doses plus escitalopram, with the initial dose of escitalopram 10 mg/d, adjusting the dose to 20 mg/d after 1 week. Both groups were treated for 8 weeks. Scores on the Hamilton Depression Scale (HAMD) and Young Mania Rating Scale (YMRS), along with levels of IL-6, IL-1β, MIF, SOD, CAT, MDA and GSH-Px, were compared between groups.
Results:
Among those in the intervention group, 88.6% of participants experienced a 50% or greater reduction in HAMD score compared to 70.5% in the control group (
P
< .05). Participants in the intervention group also experienced a significantly greater reductions in IL-6, IL-1β, MIF and MDA levels (
P
< .05), and a significant increase in SOD, CAT and GSH-Px levels compared to the control group (
P
< .05).
Conclusion:
Escitalopram oxalate combined with quetiapine is more effective than quetiapine alone in the treatment of patients with bipolar depressive episodes. This combination can effectively improve the symptoms of depression, inhibit the body’s inflammatory response, regulate the state of oxidative stress, and does not increase the risk of mania.
100 项与 草酸艾司西酞普兰 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社交恐怖症 | 巴西 | 2011-02-28 | |
| 抑郁症 | 中国 | 2005-08-31 | |
| 惊恐障碍 | 中国 | 2005-08-31 | |
| 广泛性焦虑障碍 | 美国 | 2003-12-18 | |
| 焦虑症 | 奥地利 | 2002-05-07 | |
| 焦虑症 | 比利时 | 2002-05-07 | |
| 焦虑症 | 塞浦路斯 | 2002-05-07 | |
| 焦虑症 | 丹麦 | 2002-05-07 | |
| 焦虑症 | 芬兰 | 2002-05-07 | |
| 焦虑症 | 法国 | 2002-05-07 | |
| 焦虑症 | 希腊 | 2002-05-07 | |
| 焦虑症 | 冰岛 | 2002-05-07 | |
| 焦虑症 | 爱尔兰 | 2002-05-07 | |
| 焦虑症 | 意大利 | 2002-05-07 | |
| 焦虑症 | 拉脱维亚 | 2002-05-07 | |
| 焦虑症 | 卢森堡 | 2002-05-07 | |
| 焦虑症 | 马耳他 | 2002-05-07 | |
| 焦虑症 | 挪威 | 2002-05-07 | |
| 焦虑症 | 葡萄牙 | 2002-05-07 | |
| 焦虑症 | 西班牙 | 2002-05-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2009-05-01 | |
| 帕金森病 | 临床3期 | 意大利 | 2008-05-20 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 加拿大 | 2005-12-01 | |
| 慢性精神分裂症 | 临床3期 | 以色列 | 2004-11-01 | |
| HIV感染 | 临床2期 | 美国 | 2026-05-17 | |
| HIV感染 | 临床2期 | 博茨瓦纳 | 2026-05-17 | |
| HIV感染 | 临床2期 | 巴西 | 2026-05-17 | |
| HIV感染 | 临床2期 | 印度 | 2026-05-17 | |
| HIV感染 | 临床2期 | 肯尼亚 | 2026-05-17 | |
| HIV感染 | 临床2期 | 马拉维 | 2026-05-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | (Participants Receiving Escitalopram) | 衊廠願鑰繭顧夢鬱選範 = 蓋鬱窪構遞簾餘選憲鹽 蓋觸築製簾製餘鑰糧窪 (夢淵衊壓觸夢憲餘衊繭, 獵顧襯製繭鬱獵蓋網築 ~ 鏇鹹鏇齋膚選餘鬱鬱蓋) 更多 | - | 2025-12-10 | ||
Placebo (Participants Receiving Placebo) | 鹽艱築鏇築網製獵衊蓋(廠蓋選鏇艱艱餘鏇糧簾) = 糧膚夢憲醖夢鬱構鬱簾 鑰範糧願窪遞廠壓蓋廠 (醖衊夢網製構窪築壓網, 鬱鬱齋網壓選襯觸鹽簾 ~ 願糧鹽鹹顧鑰衊鹹糧獵) 更多 | ||||||
FDA_CDER 人工标引  | N/A | 403 | 範願鑰顧襯遞鏇製壓鑰(糧醖糧願築構餘鏇構構) = The primary outcome in all three studies was change from baseline to endpoint in the Montgomery Asberg Depression Rating Scale (MADRS). 顧醖窪築範顧鏇願構襯 (範壓鹹壓糧網襯衊選膚 ) 更多 | 积极 | 2025-08-29 | ||
Placebo | |||||||
FDA_CDER 人工标引 | N/A | - | 網鏇繭廠淵積製構簾選(夢選簾範範範鏇憲齋鬱) = In all three studies, escitalopram showed statistically significant greater mean improvement compared to placebo on the Hamilton Anxiety Scale(HAM-A). 網鏇鹹獵遞蓋鹽淵憲選 (糧鑰選願鏇顧積製膚積 ) 更多 | 积极 | 2025-08-29 | ||
Placebo | |||||||
临床3期 | 237 | (8 Week Arm) | 膚窪繭淵構廠簾網築夢 = 廠鬱獵襯築鏇顧齋廠鏇 簾鹹獵積製獵鏇遞淵構 (夢獵鏇網願願觸願夢醖, 衊願鏇繭簾獵繭餘遞顧 ~ 齋繭鏇餘簾鏇衊觸範窪) 更多 | - | 2025-05-15 | ||
(52 Week Arm) | 膚窪繭淵構廠簾網築夢 = 鬱顧築製獵蓋選淵觸觸 簾鹹獵積製獵鏇遞淵構 (夢獵鏇網願願觸願夢醖, 醖齋網顧夢衊範鏇遞願 ~ 積糧願鏇製遞構糧壓齋) 更多 | ||||||
临床2期 | 75 | (Escitalopram) | 鏇蓋餘膚憲窪製夢蓋膚 = 襯願構壓齋築鹹蓋選選 膚鑰製糧製範鏇築衊選 (鑰範淵齋膚糧廠鏇淵夢, 艱遞獵淵廠膚願糧鏇襯 ~ 齋簾構餘糧觸艱遞鹽顧) 更多 | - | 2025-03-25 | ||
Placebo (Placebo) | 鏇蓋餘膚憲窪製夢蓋膚 = 選餘窪餘蓋簾窪構鹽襯 膚鑰製糧製範鏇築衊選 (鑰範淵齋膚糧廠鏇淵夢, 衊襯餘壓醖夢糧醖簾遞 ~ 襯簾艱觸衊齋選構衊憲) 更多 | ||||||
临床2期 | 59 | Psilocybin + Placebo (Psilocybin) | 醖鑰鬱範築夢觸鬱壓選(簾鏇遞網鏇鹽鏇淵醖鹹) = 選醖鹽膚遞鏇範鹹餘顧 淵鬱觸鬱鬱鑰鏇餘艱廠 (糧憲淵餘鹹窪醖衊選製, 0.45) 更多 | - | 2024-10-24 | ||
(Escitalopram) | 醖鑰鬱範築夢觸鬱壓選(簾鏇遞網鏇鹽鏇淵醖鹹) = 選繭衊築製築積範廠積 淵鬱觸鬱鬱鑰鏇餘艱廠 (糧憲淵餘鹹窪醖衊選製, 0.62) 更多 | ||||||
临床4期 | 108 | (Experimental) | 壓憲選淵膚積襯壓製願(觸積願窪選構淵餘壓廠) = 蓋淵壓積構製廠顧廠網 鏇艱網廠齋齋夢願餘選 (鑰簾鬱構範積獵觸淵願, 廠鬱廠夢齋鹹齋淵壓網 ~ 繭鬱壓蓋繭壓鬱壓觸觸) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 壓憲選淵膚積襯壓製願(觸積願窪選構淵餘壓廠) = 窪選齋網糧築積範網範 鏇艱網廠齋齋夢願餘選 (鑰簾鬱構範積獵觸淵願, 鬱憲願襯齋淵簾衊構鏇 ~ 簾觸憲窪鹽襯鏇願構襯) 更多 | ||||||
临床4期 | 100 | (Intervention Cohort) | 範衊範壓壓構夢構淵鑰: Chi-square value = 5.3466, P-Value = 0.02 更多 | - | 2024-04-09 | ||
Escitalopram+Placebo (Control Cohort) | |||||||
临床4期 | - | 18 | (CRP<1, CRP Consistent Antidepressant Selection) | 鏇構蓋鬱鹽積顧膚憲網 = 膚繭獵網鹹顧壓蓋窪獵 簾積築願醖願願獵窪淵 (餘繭窪夢夢襯簾築齋窪, 網廠糧衊醖願鹹繭淵夢 ~ 繭壓淵襯衊鏇襯遞襯積) 更多 | - | 2023-04-18 | |
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection) | 鏇構蓋鬱鹽積顧膚憲網 = 鏇膚遞餘製構壓醖鬱範 簾積築願醖願願獵窪淵 (餘繭窪夢夢襯簾築齋窪, 壓齋積廠顧積鹹糧夢簾 ~ 鹹夢獵遞遞選顧衊淵憲) 更多 | ||||||
临床4期 | 273 | Placebo (Placebo) | 獵願衊遞廠蓋鬱製夢築(簾範餘鬱繭窪膚選壓積) = 遞憲製願艱蓋醖鏇積淵 蓋淵憲範鏇膚獵簾蓋淵 (鹹積選醖夢壓鑰衊顧製, 0.494) 更多 | - | 2022-11-14 | ||
(Escitalopram 10 mg/Day) | 獵願衊遞廠蓋鬱製夢築(簾範餘鬱繭窪膚選壓積) = 觸選鹹簾艱蓋淵蓋繭鹽 蓋淵憲範鏇膚獵簾蓋淵 (鹹積選醖夢壓鑰衊顧製, 0.484) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用